COVID-19 diagnostics—not at the expense of other diseases
Priya Venkatesan
Abstract
The 2020 COVID-19 pandemic shows no signs of abating, with WHO reporting 4·9 million cases and 322 000 deaths globally as of May 21, 2020. What also shows no sign of abating is the ferocious reactive response to the pandemic—academic institutions, pharmaceutical companies, and governments alike have turned almost their whole focus to COVID-19 research, causing many health-care experts to fear that the management of other deadly diseases has been relegated to a much lower priority. The intense focus on COVID-19 might hinder the efforts and undo progress made in controlling other infectious diseases.
Topics & Concepts
PandemicCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakUndoFocus (optics)Health careBusinessPolitical scienceMedicinePublic relationsEconomic growthVirologyInfectious disease (medical specialty)EconomicsComputer scienceDiseaseOutbreakOperating systemPathologyPhysicsOpticsCOVID-19 Clinical Research Studies